{site_meta && site_meta.display_name} Logo

Reportable

Cut through the daily deluge of information from news, social media and scientific literature to better communicate to your audiences, monitor and measure your business reputation and keep a close eye on your competition.

RSS Feed for Reportable

Stonegate Updates Coverage on EnSilica PLC (AIM: ENSI) Mid-Year Update 1H 2025

June 26, 2025 — DALLAS, TX -- June 26th, 2025 -- EnSilica PLC (AIM: ENSI): Stonegate Capital Partners updates their coverage on EnSilica PLC (AIM: ENSI) during the mid-year of 1H25. Through the beginning of calendar 2025, EnSilica PLC continued to build on its strategic initiatives and market strengths, achieving significant milestones.

LEKSUM: New Study Indicates Efficacy of Multiple Doses of Extracellular Vesicles to Address Muscle Myopathy

June 24, 2025 — BOSTON, Massachusetts, June 24, 2025; A new study by Leksum LLC (Leksum) successfully demonstrates that multiple doses of extracellular vesicles (EVs) could mitigate the risk of lung injury for patients placed on mechanical ventilation (MV) while in intensive care units (ICU). Early results show significant improvement in both size and function of diaphragm muscle fibers after one dose of EVs.

UGI Urges Customers to Be Safe and Use Energy Wisely During Extreme Heat

June 23, 2025 — With excessive heat warnings in effect this week, and potentially record-breaking temperatures, UGI is offering tips to help keep the public safe and minimize energy usage. If you have a programmable thermostat and central air conditioning, raise the setting to the highest possible comfortable temperature.

Chemify Launches the World’s First Chemputation Facility Revolutionizing Molecular Design and Manufacture

June 20, 2025 — GLASGOW, Scotland – 20 June 2025 – Chemify, the deep-tech pioneer fusing chemistry, robotics, computation and AI to digitise molecule creation, today unveiled its first Chemifarm—a fully automated chemistry facility regarded as the world’s most advanced laboratory for molecular design and synthesis. Situated in Glasgow’s Maryhill district, the 21,500-ft² site unites Chemify’s AI-driven molecular-design engine with industrial-scale robotic synthesis, compressing the journey from concept to compound and accelerating the discovery of small-molecule medicines and next-generation materials for partners tackling society’s toughest challenges.

Keep A Breast Celebrates 25 Years with Anniversary Party

September 5, 2025 — YUCCA VALLEY, CA — The Keep A Breast Foundation (KAB) is thrilled to announce its 25th Anniversary Party, a one-night-only celebration in the high desert at the legendary Pappy & Harriet’s on Friday, September 5, 2025. This milestone event honors 25 years of impact, creativity, and community dedicated to breast cancer prevention and education.

BioUtah and Utah’s Life Sciences Industry Take Center Stage with Pavillion at BIO International Convention

June 12, 2025 — Salt Lake City, Utah – June 12, 2025 – BioUtah, Utah’s life sciences trade association, is proud to announce that President and CEO, Kelvyn Cullimore, along with key partners – the Governor’s Office of Economic Opportunity, World Trade Center Utah, the University of Utah Technology Licensing Office, Utah Inland Port Authority, The Point Utah, Utah Innovation Fund, Salt Lake City Dept of Economic Development, and Utah Health Entrepreneurs – will co-host the Utah Pavilion at booth #783 during the BIO International Convention, held June 16-19 in Boston, MA.  The Utah Pavilion will showcase the state's thriving life sciences sector - one of the fastest growing in the nation.

Content Carnivores LLC to Represent Global Life Sciences Clients at BIO International Convention 2025

June 12, 2025 — CHICAGO, IL and PARK CITY, UT – June 12, 2025– Content Carnivores LLC, a specialized marketing communications firm serving the global life sciences industry with offices in Chicago, Illinois and Park City, Utah, announces its participation in the BIO International Convention taking place June 16-19, 2025, at the Boston Convention and Exhibition Center. The company is excited to support the transformative developments in the biotech industry by facilitating connections between international partners and clients.

Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025

June 11, 2025 — BURLINGTON, MA – June 11, 2025 -- Lifordi Immunotherapeutics, Inc. , a biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented preclinical data on its lead program for LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells.